Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 13.9% of the patients who received trastuzumab deruxtecan (grade 1 or 2 in 33 patients and grade 3 in 1) and in 1.3% ...

Adjudicated drug-related interstitial lung disease or pneumonitis—a known adverse event related to trastuzumab deruxtecan—occurred in 12.1% (n = 46) of patients in the trastuzumab deruxtecan ...

Both trastuzumab deruxtecan-nxki (Enhertu ... Interstitial lung disease and pneumonitis occurred more frequently in the T-DXd arm (13.9% vs. 1.3%), but only one participant had a grade 3 event ...

With a median progression-free survival of more than three years, the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new first-line ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically significant and ...

The DESTINY-Breast11 study is pitting Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) against standard care – chemotherapy followed by THP as a pre ...

Datroway is the second ADC brought to market by AZ and Daiichi Sankyo after Enhertu (trastuzumab deruxtecan), an HER2-targeting ADC that brought in sales of more than $2.7 billion in the first ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...